Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where V. Weich is active.

Publication


Featured researches published by V. Weich.


Journal of Clinical Virology | 2011

Long-term evaluation of patients with sustained virologic remission by highly sensitive HCV RNA assays: no evidence for viral persistence.

B Schlosser; M. Biermer; V. Weich; F. van Bömmel; T. Berg

The induction of a sustained virologic response (SVR) in hepatitis virus (HCV) infected patients, defined as undetectable serum HCV NA levels 6 months after stopping therapy, is believed to herald he determination of the chronic HCV infection.1,2 However, recent ndings suggest that residual HCV RNA can persist in PBMC, lymhatic or liver tissue3–5 indicating that minimal residual hepatitis viremia can escape standard HCV RNA assays.6 Now Fytili et al. eported in this Journal that, minimal residual HCV RNA can be etected in more than 20% of SVR patients when serum samples ere tested with a highly sensitive RealTime PCR assay (Abbott, 2000 RealTime PCR).7 To further substantiate these findings, we re-evaluated 160 erum samples of 145 SVR patients with two different highly senitive HCV RNA assays, the Abbott RealTime PCR (m2000rt) system nd the Siemens Versant TMA® assay. Two different RNA extraction ethods were applied for the RealTime PCR assay: the manual RNA xtraction method was used in 97 patients while the automated ersion was employed in 63 patients. Median time after EOT was .1 years (range: 0.5–12 y). By using the TMA assay, only one sample out of 160 was found to e HCV-RNA positive (0.6%). In contrast, in 10% (n = 16) of the SVR atients HCV RNA was detectable by the RealTime PCR. 14 out of hese 16 positive samples have been treated by the manual extracion method (14.5% of those analysed manually, 9% of all), whereas CV RNA could be detected only in 2 out of 63 patients (3.2%, 1.4% of ll) when the fully automated version of the assay was applied. All ut one of the HCV RNA positive samples had levels below the limit f quantification of the assay (i.e. <12 IU/mL) see Fig. 1. But most mportantly, in none of the patient the positive HCV RNA result ould be confirmed by the TMA assay or vice versa. These findings ould be also confirmed by testing a second serum sample from a ifferent time point in 8 out of the 16 HCV RNA positive patients. oth assays, the TMA and the fully automated RealTime PCR test ave negative results. Thus our study contradicts Fytili’s conclusion and rather indiates that positive HCV RNA signals detectable by RealTime PCR re due to either unspecific amplification or contamination. This nterpretation is strengthens by our finding that the ratio of HCV NA positive samples by real time PCR was significantly higher hen using the manual extraction (14.5%) as compared to the fully utomated system (3%). We argue that most probably false posi-


Journal of Hepatology | 2008

709 LONG-TERM TREATMENT WITH LAMIVUDINE UP TO TEN YEARS: PREDICTIVE VALUE OF HOST AND VIRUS RELATED RISK FACTORS FOR THE DEVELOPMENT OF HBV RESISTANCE

F. van Bömmel; A. Brodzinski; U. Mihm; M. C. Jung; C. Sarrazin; A. Bergk; B Schlosser; V. Weich; Tobias Müller; Eckart Schott; Bertram Wiedenmann; T. Berg


Journal of Hepatology | 2012

912 APOLIPOPROTEIN E4 ALLELE PROTECTS FROM CHRONIC HCV INFECTION

Tobias Müller; Janett Fischer; Jonas Rosendahl; Stephan H. Bohm; F. van Bömmel; Johannes Wiegand; R. Gessner; V. Weich; C. Sarrazin; Heiko Witt; A. Bergk; Eckart Schott; Bertram Wiedenmann; T. Berg


Bohm, S., Fischer, J., van Bommel, F., Weich, V., Teuber, G., Klinker, H., Moeller, B., Rasenack, J., Hinrichsen, H., Gerlach, T., Spengler, U., Buggisch, P., Sarrazin, C. and Berg, T. (2011) ANALYSIS OF IL28B GENOTYPE FOR THE SELECTION OF PATIENTS FOR AN INDIVIDUALIZED TREATMENT DURATION IN HCV GENOTYPE 1 PATIENTS (THE INDIV-1 STUDY) Hepatology, 54 . 818A-819A. | 2011

ANALYSIS OF IL28B GENOTYPE FOR THE SELECTION OF PATIENTS FOR AN INDIVIDUALIZED TREATMENT DURATION IN HCV GENOTYPE 1 PATIENTS (THE INDIV-1 STUDY)

Stephan H. Bohm; Janett Fischer; F. van Bommel; V. Weich; G. Teuber; H Klinker; B. Moeller; J. Rasenack; Holger Hinrichsen; T. Gerlach; Ulrich Spengler; Peter Buggisch; C. Sarrazin; T. Berg


Zeitschrift Fur Gastroenterologie | 2009

Ursodeoxycholic acid normalizes the 15 years survival in German patients with primary biliary cirrhosis and normal serum bilirubin levels at baseline

M. Pascu; K. Neumann; P Martus; B Schlosser; A Felder; V. Weich; M. Biermer; F van Bömmel; Dc Baumgart; Bertram Wiedenmann; T. Berg


Zeitschrift Fur Gastroenterologie | 2008

Langzeitnachbeobachtung von HCV-infizierten Patienten mit anhaltender virologischer Response mittels hoch-sensitiver HCV-RNA Tests (Abbott vs. TMA): Hinweise für minimale Restvirämie?

B Schlosser; M. Biermer; F van Bömmel; V. Weich; M. Chauvel; Bertram Wiedenmann; T. Berg


Zeitschrift Fur Gastroenterologie | 2008

Prognose von Patienten mit primär sklerosierender Cholangitis (PSC): Langzeitverlaufsdokumentation über durchschnittlich 9 Jahre aus einem Zentrum

M. Chauvel; M. Biermer; B Schlosser; J. Weltke; Eckart Schott; F van Bömmel; V. Weich; Tobias Müller; A. Bergk; Bertram Wiedenmann; T. Berg


Zeitschrift Fur Gastroenterologie | 2008

Lamivudin (LMV) in der Langzeittherapie der chronischen Hepatitis B Virus (HBV)-Infektionen bis zu zehn Jahren: Bedeutung von Wirts- und viralen Faktoren für die Resistenzentwicklung

F van Bömmel; A. Brodzinski; K. Neumann; U. Mihm; M. C. Jung; C. Sarrazin; B Schlosser; V. Weich; Eckart Schott; Tobias Müller; M. Biermer; M. Chauvel; Bertram Wiedenmann; T. Berg


Zeitschrift Fur Gastroenterologie | 2008

Vergleich zweier hoch-sensitiver HCV RNA Tests hinsichtlich ihrer prognostischen Relevanz für die Vorhersage des langfristigen Therapieansprechens bei HCV Typ 1 infizierten Patienten: Abbott RealTime PCR vs. Siemens VERSANT(R)-TMA Test

B Schlosser; M. Biermer; V. Weich; F van Bömmel; M. Chauvel; Bertram Wiedenmann; T. Berg


Zeitschrift Fur Gastroenterologie | 2007

Multifaktorielle Analyse des Einflusses von viralen und Wirtsfaktoren bei der Resistenzentwicklung in der Lamivudin-Langzeittherapie von HBV-Infektionen bis zu zehn Jahren

F van Bömmel; A. Brodzinski; U. Mihm; M. C. Jung; C. Sarrazin; B Schlosser; V. Weich; Eckart Schott; Bertram Wiedenmann; T. Berg

Collaboration


Dive into the V. Weich's collaboration.

Top Co-Authors

Avatar

T. Berg

Royal Netherlands Academy of Arts and Sciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

C. Sarrazin

Goethe University Frankfurt

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

U. Mihm

Goethe University Frankfurt

View shared research outputs
Researchain Logo
Decentralizing Knowledge